APSR2026-511

 
Late-Breaking
Submitted
Oral Presentation
AO33-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1220741-46903-APSR-AO33-003_440950.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

David Ngo * St George Hospital Department of Respiratory and Sleep Medicine Sydney Australia
Emily Liu - St George Hospital Department of Respiratory and Sleep Medicine Sydney Australia
Joshua Banner - St George Hospital Department of Respiratory and Sleep Medicine Sydney Australia
Marcela Arias-Alvarez - St George Hospital Department of Respiratory and Sleep Medicine Sydney Australia
Vicky Chang - St George Hospital Department of Respiratory and Sleep Medicine Sydney Australia
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
David
Ngo
davidngo34@gmail.com
+61450030374
Under 30
Australia
Original Research
Implementation of fixed-dose combination 12-week once-weekly rifapentine–isoniazid regimen for latent tuberculosis infection: Early programmatic experience from an Australian tuberculosis service
Maximum 25 words
Abstract Content
Treatment of latent tuberculosis infection (LTBI) is a cornerstone of the World Health Organization End TB Strategy. An open-label randomised controlled trial demonstrated that the 12-week once-weekly rifapentine–isoniazid regimen (3HP) is non-inferior to nine months of isoniazid (9H); however, these regimens are associated with a substantial pill burden and access to rifapentine has historically been limited in Australia. This study aimed to evaluate the use of fixed-dose combination (FDC) 3HP among individuals with LTBI.
A retrospective cohort study was conducted among patients diagnosed with latent tuberculosis infection (LTBI) and treated with fixed-dose combination (FDC) 3HP at a metropolitan Sydney chest clinic between October 2025 and February 2026. During this period, there was a shortage of rifampicin within the NSW Tuberculosis Program. Clinical characteristics and diagnostic test results were extracted from medical records. Data were analysed using descriptive statistics. All doses were self-administered, and participants received weekly SMS reminders. Collected data included demographic characteristics, treatment completion, adverse events, and participant satisfaction.
The study identified 46 patients treated with FDC 3HP. The median age was 35.5 years (IQR 28.3–51.3), and the majority were born overseas. Treatment completion was achieved in 42/46 patients (91.3%). Adverse events (AE) were reported in 15/46 patients (32.6%), no grade 4 or above AEs were reported. Patient satisfaction was also assessed using a questionnaire.
The FDC 3HP regimen, supported by SMS reminders, was well tolerated and associated with high treatment completion. This study demonstrated the feasibility and acceptability of the 3HP regimen in LTBI treatment in Australian context. These findings support broader implementation of FDC 3HP in treatment for TBI to improve adherence and treatment outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
tuberculosis infection, rifapentine–isoniazid (3HP), treatment completion
maximum 3 keywords and no abbreviations, separated by commas
 
277